178 related articles for article (PubMed ID: 35312724)
1. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma.
Sangsuwannukul T; Supimon K; Chieochansin T; Choomee K; Sujjitjoon J; Junking M; Yenchitsomanus PT
PLoS One; 2022; 17(3):e0265773. PubMed ID: 35312724
[TBL] [Abstract][Full Text] [Related]
2. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
Biomed Pharmacother; 2024 May; 175():116718. PubMed ID: 38744221
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1.
Luangwattananun P; Sangsuwannukul T; Supimon K; Thuwajit C; Chieochansin T; Sa-Nguanraksa D; Samarnthai N; O-Charoenrat P; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2023 Nov; 124(Pt B):111012. PubMed ID: 37804657
[TBL] [Abstract][Full Text] [Related]
4. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
Sangsuwannukul T; Supimon K; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107069. PubMed ID: 33242709
[TBL] [Abstract][Full Text] [Related]
6. Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
Wathikthinnakon M; Luangwattananun P; Sawasdee N; Chiawpanit C; Lee VS; Nimmanpipug P; Tragoolpua Y; Rotarayanont S; Sangsuwannukul T; Phanthaphol N; Wutti-In Y; Somboonpatarakun C; Chieochansin T; Junking M; Sujjitjoon J; Yenchitsomanus PT; Panya A
Sci Rep; 2022 Apr; 12(1):6154. PubMed ID: 35418130
[TBL] [Abstract][Full Text] [Related]
7. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
8. Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.
Petersburg J; Vallera DA; Wagner CR
Mol Cancer Ther; 2023 Mar; 22(3):371-380. PubMed ID: 36548194
[TBL] [Abstract][Full Text] [Related]
9. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
10. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
11. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.
Liu R; Zhao R; Zhou X; Liang X; Campbell DJ; Zhang X; Zhang L; Shi R; Wang G; Pandak WM; Sirica AE; Hylemon PB; Zhou H
Hepatology; 2014 Sep; 60(3):908-18. PubMed ID: 24700501
[TBL] [Abstract][Full Text] [Related]
12. The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.
Samatiwat P; Tabtimmai L; Suphakun P; Jiwacharoenchai N; Toviwek B; Kukongviriyapan V; Gleeson MP; Choowongkomon K
Asian Pac J Cancer Prev; 2021 Feb; 22(2):381-390. PubMed ID: 33639651
[TBL] [Abstract][Full Text] [Related]
13. Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.
Thepmalee C; Panya A; Sujjitjoon J; Sawasdee N; Poungvarin N; Junking M; Yenchitsomanus PT
Hum Vaccin Immunother; 2020 Oct; 16(10):2318-2327. PubMed ID: 31976810
[TBL] [Abstract][Full Text] [Related]
14. The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers.
van Diest E; Nicolasen MJT; Kramer L; Zheng J; Hernández-López P; Beringer DX; Kuball J
Front Immunol; 2022; 13():1052090. PubMed ID: 36685546
[TBL] [Abstract][Full Text] [Related]
15. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
16. Adaptor protein XB130 regulates the aggressiveness of cholangiocarcinoma.
Poosekeaw P; Pairojkul C; Sripa B; Sa Ngiamwibool P; Iamsaard S; Sakonsinsiri C; Thanan R; Ungarreevittaya P
PLoS One; 2021; 16(11):e0259075. PubMed ID: 34780466
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
18. Silencing of CXCR4 inhibits tumor cell proliferation and neural invasion in human hilar cholangiocarcinoma.
Tan XY; Chang S; Liu W; Tang HH
Gut Liver; 2014 Mar; 8(2):196-204. PubMed ID: 24672662
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma.
Cadamuro M; Nardo G; Indraccolo S; Dall'olmo L; Sambado L; Moserle L; Franceschet I; Colledan M; Massani M; Stecca T; Bassi N; Morton S; Spirli C; Fiorotto R; Fabris L; Strazzabosco M
Hepatology; 2013 Sep; 58(3):1042-53. PubMed ID: 23505219
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a novel human cholangiocarcinoma cell line with high metastatic activity.
Uthaisar K; Vaeteewoottacharn K; Seubwai W; Talabnin C; Sawanyawisuth K; Obchoei S; Kraiklang R; Okada S; Wongkham S
Oncol Rep; 2016 Sep; 36(3):1435-46. PubMed ID: 27461717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
